ABSTRACT
BACKGROUND: Polypharmacy for treatment of depression has been increasing in Taiwan. METHODS: Individuals having depressive disorders were identified in a national database for healthcare services and followed up for 5 years. The mean dosage of antidepressants, antipsychotics, mood stabilizers, and sedative-hypnotics was calculated; the associations between the exposure dosage to different psychotropic medications and patients' overall death and death due to cardiovascular diseases (CVD) and suicide were examined. RESULTS: A total of 400,042 individuals with depressive disorders (63.8% women) were identified. Compared with those with no exposure to antidepressants, patients prescribed antidepressants had decreased mortality. Use of antipsychotics had a dose-related increase in overall mortality risk compared to no exposure group. Contrarily, depressed patients taking sedative-hypnotics had decreased overall and CVD mortality compared to no exposure group, with the most prominent decrease in CVD mortality of up to 54.9% for those in the moderate exposure group (hazard ratio: 0.451, 95% confidence interval: 0.405-0.503). A moderate or high dose of antidepressants or sedative-hypnotics was shown to be associated with a significantly increased mortality for suicide compared to those with no exposure. CONCLUSIONS: Antidepressant and sedative-hypnotic use was associated with decreased all-cause and CVD-related mortality and use of antipsychotics was associated with a dose-related increase in mortality risk. Future studies are needed to further clarify the involved mechanisms and benefits and risks should be carefully weighed when prescribing psychotropic medications in patients with depressive disorders.
Subject(s)
Cardiovascular Diseases , Depressive Disorder , Psychotropic Drugs , Suicide , Humans , Taiwan/epidemiology , Cardiovascular Diseases/mortality , Cardiovascular Diseases/epidemiology , Female , Male , Middle Aged , Adult , Suicide/statistics & numerical data , Depressive Disorder/drug therapy , Depressive Disorder/mortality , Depressive Disorder/epidemiology , Psychotropic Drugs/adverse effects , Psychotropic Drugs/therapeutic use , Aged , Antidepressive Agents/adverse effects , Antidepressive Agents/administration & dosage , Antipsychotic Agents/adverse effects , Antipsychotic Agents/administration & dosage , Hypnotics and Sedatives/adverse effects , Hypnotics and Sedatives/administration & dosage , Young AdultABSTRACT
OBJECTIVES: Electroconvulsive therapy (ECT) is effective in treating late-life depression. There is limited research on suicidal behavior and all-cause mortality in the oldest old after ECT. METHODS: Older adults aged 75 years and above who had been inpatients for moderate to severe depression between January 1, 2011, and December 31, 2017, were included in the study. We used exact and propensity score matching to balance groups. We compared suicidal behavior (fatal and non-fatal) and all-cause mortality in those who had received ECT and those with other depression treatments. RESULTS: Of the study population, 1802 persons who received ECT were matched to 4457 persons with other treatments. There were no significant differences in the risk of suicidal behavior between groups, (within 3 months: odds ratio 0.73; 95% confidence intervals (CI), 0.44-1.23, within 4 months to 1 year: aOR 1.34; 95% CI, 0.84-2.13). All-cause mortality was lower among ECT recipients compared to those who had received other treatments, both within 3 months (aOR, 0.35; 95% CI, 0.23-0.52), and within 4 months to 1 year (aOR 0.65; 95% CI, 0.50-0.83). CONCLUSIONS: Compared to other depression treatments, ECT is not associated with a higher risk of suicidal behavior in patients aged 75 and above. ECT is associated with lower all-cause mortality in this age group, but we advise caution regarding causal inferences.
Subject(s)
Electroconvulsive Therapy , Registries , Humans , Electroconvulsive Therapy/mortality , Female , Male , Aged , Sweden , Aged, 80 and over , Suicidal Ideation , Propensity Score , Depressive Disorder/therapy , Depressive Disorder/mortality , Cause of DeathABSTRACT
BACKGROUND: New National Institute for Health and Care Excellence (NICE) guidance endorses the prescription of statins in larger population groups for the prevention of cardiovascular and cerebrovascular morbidity and mortality, especially in people with severe mental illness. However, the evidence base for their safety and risk/benefit balance in depression is not established. OBJECTIVES: This study aims to assess the real-world mortality and adverse events of statins in depressive disorders. METHODS: Population-based, nationwide (England), between-subject, cohort study. We used electronic health records (QResearch database) of people aged 18-100 years with first-episode depression, registered with English primary care practices over January 1998-August 2020 for 12(+) months, divided into statin users versus non-users.Primary safety outcomes included all-cause mortality and any adverse event measured at 2, 6 and 12 months. Multivariable logistic regression was employed to control for several potential confounders and calculate adjusted ORs (aORs) with 99% CIs. FINDINGS: From over 1 050 105 patients with depression (42.64% males, mean age 43.23±18.32 years), 21 384 (2.04%) died, while 707 111 (67.34%) experienced at least one adverse event during the 12-month follow-up. Statin use was associated with lower mortality over 12 months (range aOR2-12months 0.66-0.67, range 99% CI 0.60 to 0.73) and with lower adverse events over 6 months (range aOR2-6months 0.90-0.96, range 99% CI 0.91 to 0.99), but not at 1 year (aOR12months 0.99, 99% CI 0.96 to 1.03). No association with any other individual outcome measure (ie, any other neuropsychiatric symptoms) was identified. CONCLUSIONS: We found no evidence that statin use among people with depression increases mortality or other adverse events. CLINICAL IMPLICATIONS: Our findings support the safety of updated NICE guidelines for prescribing statins in people with depressive disorders.
Subject(s)
Hydroxymethylglutaryl-CoA Reductase Inhibitors , Primary Health Care , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Male , Female , Adult , Middle Aged , Primary Health Care/statistics & numerical data , Aged , Cohort Studies , Adolescent , Aged, 80 and over , Young Adult , England/epidemiology , Depressive Disorder/drug therapy , Depressive Disorder/mortality , Depressive Disorder/epidemiology , Depression/drug therapy , Depression/epidemiologySubject(s)
Humans , Male , Female , Adult , Middle Aged , Young Adult , Fatigue Syndrome, Chronic/mortality , Depressive Disorder/mortality , Suicide/statistics & numerical data , Wales , Fatigue Syndrome, Chronic/psychology , Registries , Retrospective Studies , Cohort Studies , England , Neoplasms/mortalityABSTRACT
No disponible
Subject(s)
Humans , Depression/epidemiology , Hospitalization/statistics & numerical data , Hospital Mortality , Primary Health Care/statistics & numerical data , Depressive Disorder/mortalityABSTRACT
No disponible
No disponible